Potential roles of antisense technology in cancer chemotherapy
- 27 December 2000
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 19 (56), 6651-6659
- https://doi.org/10.1038/sj.onc.1204093
Abstract
Antisense technology may play a major role in cancer chemotherapy. It is clearly a tool of exceptional value in the functionalization of genes and their validation as potential targets for cancer chemotherapy. Additionally, there is now substantial evidence that antisense drugs are safe, and a growing body of data showing activity in animal models of human disease including cancer, and suggesting efficacy in patients with cancer. In this article, I review the progress in the technology, the anticancer antisense drugs in development and potential roles that antisense technology might play.Keywords
This publication has 51 references indexed in Scilit:
- Evaluating the Mechanism of Action of Antiproliferative Antisense DrugsAntisense and Nucleic Acid Drug Development, 2000
- Regular featureJournal of Perinatology, 1999
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion SystemAntisense and Nucleic Acid Drug Development, 1996
- Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapyKidney International, 1995
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993
- Uniformly modified 2'-deoxy-2'-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targetsJournal of Medicinal Chemistry, 1993
- Therapeutic Applications of OligonucleotidesAnnual Review of Pharmacology and Toxicology, 1992
- Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix FormationScience, 1989
- Interferon Induction Increased through Chemical Modification of a Synthetic PolyribonucleotideScience, 1969